By continuing to use this site, you consent to our use of cookies to personalize your experience and to analyze website traffic. Learn more in our Privacy Policy.

Accept
Privacy Policy

See RELiZORB real-world results #

#
Upcoming Educational Programs
#
RELiZORB (iMMOBILIZED LIPASE) CARTRIDGE

Review Real-World Case Studies

Hear from your peers about how they are using RELiZORB in real patient case studies

Short bowel syndrome (SBS)

Case study video featuring Dr. Candi Jump and Kelly Tappenden discussing a 16-year-old male with SBS

Short bowel syndrome

16-year-old male with SBS

Presented by Dr. Candi Jump, DO, MSED, CNSC. Moderated by Kelly Tappenden, PhD, RD

Download case study #

Case study video featuring Dr. Hillary Bashaw and Kelly Tappenden discussing a 10-year-old female with SBS

Short bowel syndrome

10-year-old female with SBS

Presented by Hillary Bashaw, MD. Moderated by Kelly Tappenden, PhD, RD

Download case study #

Case study video featuring Dr. Debora Duro and Kelly Tappenden discussing a 7-year-old male with SBS

Short bowel syndrome

7-year-old male with SBS

Presented by Debora Duro, MD, MS. Moderated by Kelly Tappenden, PhD, RD

Download case study #

Case study video featuring Dr. Valeria Cohran and Kelly Tappenden discussing a 6-year-old female with SBS

Short bowel syndrome

6-year-old female with SBS

Presented by Valeria Cohran, MD. Moderated by Kelly Tappenden, PhD, RD

Download case study #

Meet Caleb, a 6-year-old boy with SBS

Video thumbnail featuring Dr. Sivan Kinberg sharing her perspective on treating her patient, Caleb, for SBS with RELiZORB

Short bowel syndrome

Caleb’s Story: A Doctor’s Perspective

Sivan Kinberg, MD

Video thumbnail featuring Dr. Sivan Kinberg, her patient Caleb, and his caregiver discussing collaborative care with RELiZORB

Short bowel syndrome

Caleb’s Story: Collaborative Care

Sivan Kinberg, MD

Exocrine pancreatic insufficiency (EPI)

RELiZORB expert case-study videos - Kay Vavrina

Cystic fibrosis

13-year-old female with pancreatic insufficiency

Kay Vavrina, BS, MPA, RD, LD, CNSC

#

Oncology

84-year-old male diagnosed with pancreatic adenocarcinoma

Jaclyn Moore, MS, RD, CSO

RELiZORB expert case-study videos - Whitney Christe, 73-year-old with pancreatic cancer and pancreatectomy

Oncology

73-year-old male with pancreatic cancer and pancreatectomy

Whitney Christie, MS, RD, CSO, CNSC

RELiZORB expert case-study videos - Whitney Christe, 70-year-old male with pancreatic cancer and pancreaticoduodenectomy

Oncology

70-year-old male with pancreatic cancer and pancreaticoduodenectomy

Whitney Christie, MS, RD, CSO, CNSC

RELiZORB expert case-study videos - Jaclyn Moore

Oncology + pancreatitis

73-year-old male with nasopharyngeal squamous cell carcinoma and pancreatitis

Jaclyn Moore, MS, RD, CSO

RELiZORB expert case-study videos - Melissa Wallinga

Critical care

6-year-old GJ-tube–dependent male admitted to the pediatric ICU

Melissa Wallinga, MS, RD, CSPCC, LD

Image of the downloadable RELiZORB Fat Malabsorption Patient Identification Guide

RELiZORB Fat Malabsorption Patient Identification Guide

Fat malabsorption is challenging to identify in at-risk patients due to similarities with many other gastrointestinal conditions. Download the Fat Malabsorption Patient Identification Guide for further insight.1,2

Download guide #

Photo of Dr. Kinberg administering enteral nutrition through RELiZORB to Caleb while his mom, Kayleigh, observes

Caleb, a child who tube feeds with RELiZORB, his mom, Kayleigh, and doctor, Sivan Kinberg

See how RELiZORB can help support you and your patients

Explore support and resources

#

References: 1. Alkaade S, Vareedayah AA. A primer on exocrine pancreatic insufficiency, fat malabsorption, and fatty acid abnormalities. Am J Manag Care. 2017;23(suppl 12):S203-S209 2. Singh VK, Haupt ME, Geller DE, Hall JA, Quintana Diez PM. Less common etiologies of exocrine pancreatic insufficiency. World J Gastroenterol. 2017;23(39):7059-7076. doi:10.3748/wjg.v23.i39.7059

RELiZORB is indicated for use in pediatric (including neonates and infants) and adult patients to hydrolyze fats during enteral feeding.

Warnings
  • RELiZORB is for use with enteral tube feeding only.
See more
#

RELiZORB is indicated for use in pediatric (including neonates and infants) and adult patients to hydrolyze fats during enteral feeding.

Warnings
  • RELiZORB is for use with enteral tube feeding only.
  • RELiZORB should not be connected to any intravenous (IV) line, setup, or system.
  • Medications should not be administered through the RELiZORB cartridge. Do not add medications to the enteral nutrition or tubing before RELiZORB. The passage of medications through RELiZORB may adversely affect the medications or the ability of RELiZORB to hydrolyze fats.
  • Fibrosing Colonopathy - Fibrosing colonopathy is a rare, serious adverse reaction associated with high-dose use of pancreatic enzyme replacement therapy in the treatment of patients with cystic fibrosis. The underlying mechanism of fibrosing colonopathy remains unknown. Patients with fibrosing colonopathy should be closely monitored because some patients may be at risk of progressing to stricture formation. RELiZORB contains lipase enzyme that is not from a porcine source. The lipase is bound to the beads, and this lipase-bead complex (iLipase) is retained within the RELiZORB cartridge. Continue to follow your physician’s guidance and porcine pancreatic enzyme labeling regarding porcine pancreatic enzyme use when used in conjunction with RELiZORB.
Cautions and Precautions
  • Do not re-use RELiZORB. RELiZORB is a single-use product. Re-use may result in contamination of the product. If re-used, RELiZORB may not effectively hydrolyze fats.
  • Do not break, alter, or place excess pressure on any part of RELiZORB. Any compromise of the structural integrity of RELiZORB may lead to improper connection to enteral feeding supplies, leakage or risk of contamination.
  • Do not use RELiZORB after the date marked on the pouch.
  • Enteral nutrition administered through RELiZORB is for immediate consumption through an enteral feeding tube. RELiZORB should not be used to process enteral nutrition for later use. This has not been tested and may result in safety issues.
  • RELiZORB is designed for use with enteral feeding pump systems with low flow/no flow alarms and enteral syringes for manual bolus by syringe (push or gravity). A detailed listing of enteral nutrition, pumps, and enteral feeding supplies compatible with RELiZORB can be found at www.relizorbhcp.com/compatibility.
  • Patients less than 1 year old may be particularly vulnerable to unplanned interruptions of feeding.
  • Do not use blenderized formulas with RELiZORB. A detailed listing of enteral nutrition compatible with RELiZORB can be found at www.relizorbhcp.com/compatibility.
  • Powdered formulas should be mixed periodically during feedings.
  • Do not use excessive force on the plunger when using RELiZORB with bolus syringe feeding method.
  • Do not rush bolus feeds. Follow guidance from your healthcare professional on how long it should take you to complete your tube feeding. Ensure all inlet and outlet connectors on RELiZORB and enteral feeding supplies are clean and dry prior to making connections.
  • In order to ensure product performance, store RELiZORB in its pouch either refrigerated or at room temperature (2°C to 27°C; 36°F to 80°F).
  • RELiZORB is indicated for use with enteral feeding only; patients should follow physician’s guidance for pancreatic enzyme replacement therapy (PERT) use for meals and snacks. Patients and patient caregivers should follow physician’s guidance regarding the need for pancreatic enzyme replacement therapy (PERT) during enteral feeding.

Review full product information for RELiZORB in the Instructions for Use.